Pseudomonas aeruginosais a cause of high mortality in burn, immunocompromised, and surgery patients. High incidence of antibiotic resistance in this pathogen makes the existent therapy inefficient. Type three secretion system (T3SS) is a leading virulence system ofP. aeruginosathat actively suppresses host resistance and enhances the severity of infection. Innovative therapeutic strategies aiming at inhibition of type three secretion system ofP. aeruginosaare highly attractive, as they may reduce the severity of clinical manifestations and improve antibacterial immune responses. They may also represent an attractive therapy for antibiotic-resistant bacteria. Recently our laboratory developed a new small molecule inhibitor belonging to a class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones, Fluorothiazinon (FT), that effectively suppressed T3SS in chlamydia and salmonellain vitroandin vivo.In this study, we evaluate the activity of FT towards antibiotic-resistant clinical isolates ofP. aeruginosaexpressing T3SS effectors ExoU and ExoS in an airway infection model. We found that FT reduced mortality and bacterial loads and decrease lung pathology and systemic inflammation. In addition, we show that FT inhibits the secretion of ExoT and ExoY, reduced bacteria cytotoxicity, and increased bacteria internalizationin vitro. Overall, FT shows a strong potential as an antibacterial therapy of antibiotic-resistantP. aeruginosainfection.
Shutting DownShigellaSecretion: Characterizing Small Molecule Type Three Secretion System ATPase Inhibitors
